Spanish researchers have observed how the use of ivermectin in patients with moderate coronavirus reduces the viral load and the duration of certain symptoms compared with the placebo group. The conclusion is still preliminary.
A kind Clinical Trials It is recommended to manage as soon as possible Ivermectin Can be reduced Viral load The duration of the patient’s symptoms Coronavirus disease Moderate, this can also reduce spread Viral.The research is part of the research SAINT projectBy the University Clinic of Navarra and the Barcelona Institute of Global Health (global), a center initiated by the “la Caixa” Foundation.
There are already two vaccine Passed the new coronavirus In the EU, but it will take at least two years immunity It accounts for a high enough proportion of the world’s population and prevents the spread of the virus. At the same time, it is necessary to find drugs that can treat or prevent infections.
“Significant efforts are being made to develop therapies for COVID-19, but people are paying less attention to finding drugs that reduce the spread of the virus. virus“,Say Carlos Chaccour, The pilot coordinator published in the magazine Clinical medicine, Belongs to the group Lancet.
Chaccour’s team hopes to assess whether the maximum dose of ivermectin approved in Europe will affect the spread of the virus if it is administered quickly after the onset of symptoms.
Ivermectin is Antiparasitic drugs as the picture shows in vitro, Can reduce duplication SARS-CoV-2; Although its concentration is much higher than the recommended human concentration. This and the results of preliminary human research- Suspicious source data And it has never been published in a scientific journal-leading to ivermectin being used by many people Latin American countries Although there is a lack of reliable evidence to prove its efficacy in preventing or treating infections.
Need for larger trials
Within 72 hours after the first symptoms appeared in this group, 24 patients with confirmed infections and moderate symptoms were given a single dose of ivermectin or a placebo. Nasopharyngeal swabs and blood samples were taken at recruitment and 1, 2 or 3 weeks after treatment.
After 7 days of treatment, there was no difference in the percentage of PCR-positive patients (100% of patients in both groups were positive). However, the median viral load of the group treated with ivermectin was lower (about a 3-fold reduction after four days, and as much as 18-fold reduction after 7 days), although there was no statistically significant difference.
Patients in the treatment group also showed a reduction in the duration of certain symptoms (loss of smell and taste by 50%, and loss of cough by 30%). All patients developed IgG antibodies against the virus, but again, the average value of these antibodies in the treatment group was lower than the placebo group. Chaccour said: “This may reflect the lower viral load of these patients.”
The fact that there is no difference in the duration of inflammation-related symptoms or markers suggests that ivermectin may work through another mechanism that has nothing to do with possible anti-inflammatory effects. As a study conducted by the Pasteur Institute in hamsters showed, the research team suggested that it might interfere with the entry of viruses into cells.
Chaccour said: “These results are consistent with recent trials in Bangladesh and Argentina.” “Although this study is small, it is still too early to conclude, but the observed viral load is reduced, symptom duration and antibodies The downward trend in levels is encouraging and justifies the conduct of large-scale, larger-scale controlled clinical studies, he concluded.
Chaccour C, Casellas A, Blanco-Di Matteo A, etc. The effect of ivermectin early treatment on the viral load, symptoms and humoral response of patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. Clinical medicine. 2021. DOI: 10.1016 / j.eclinm.2020.100720